Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Prostatic Neoplasms 17Prostatic Neoplasms, Castration-Resistant 2Neoplasms 2Neoplasm Metastasis 2Metastatic Hormone-sensitive Prostate Cancer 2Metastatic Castration-Resistant Prostate Cancer 2Adenocarcinoma 2Small Cell Lung Carcinoma 1Recurrence 1Prostate Adenocarcinoma 1PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy 1Metastatic Castration-resistant Prostate Neoplasms 1Metastatic Castration-resistant Prostate Cancer 1Lymphoma, Follicular 1Colorectal Neoplasms 1Castrate Sensitive Prostate Cancer 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Bites and Stings 1Advanced Prostate Cancer 1

Interventions

Bevacizumab 26Cetuximab 24Fluorouracil 23Leucovorin 22Oxaliplatin 19pembrolizumab 18Specimen Handling 11Irinotecan 10Nivolumab 8Magnetic Resonance Spectroscopy 8atezolizumab 7Biopsy 7Pemetrexed 6Panitumumab 6Cisplatin 6Carboplatin 6trifluridine tipiracil drug combination 5fludarabine 5encorafenib 5HMPL-013 5Gemcitabine 5Folfox protocol 5Standard of Care 4Immunoglobulin G 4Disulfides 4Cyclophosphamide 4zanidatamab 3regorafenib 3fludarabine phosphate 3dehydroftorafur 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colorectal Neoplasms × enzalutamide × 30 days × Clear all
NCT07620574 2026-06-02

Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study

Exelixis

Phase 3 Not yet recruiting
5,000 enrolled
GastrointestinalGenitourinary

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡